Literature DB >> 24665112

Positron emission tomography assessment of large vessel inflammation in patients with newly diagnosed, biopsy-proven giant cell arteritis: a prospective, case-control study.

Sergio Prieto-González1, Marina Depetris2, Ana García-Martínez3, Georgina Espígol-Frigolé1, Itziar Tavera-Bahillo1, Marc Corbera-Bellata1, Ester Planas-Rigol1, Marco A Alba1, José Hernández-Rodríguez1, Josep M Grau4, Franciso Lomeña2, Maria C Cid1.   

Abstract

BACKGROUND: Positron emission tomography (PET) scan is emerging as a promising imaging technique to detect large-vessel inflammation in giant cell arteritis (GCA). However, the lack of a standardised definition of arteritis based on (18)fluorodeoxyglucose (FDG) uptake is an important limitation to the use of PET scan for diagnostic purposes.
OBJECTIVE: To prospectively assess the intensity and distribution of FDG uptake at different vascular territories in patients with newly diagnosed GCA compared with controls.
METHODS: 32 consecutive, biopsy-proven, GCA patients treated with glucocorticoids for ≤3 days were included. The control group consisted of 20 individuals, who underwent PET/CT for cancer staging. Maximal standardised uptake value (SUVm) was calculated at four aortic segments, supraaortic branches and iliac-femoral territory. Sensitivity and specificity was calculated by receiver-operator characteristic curves (ROC) analysis.
RESULTS: Mean SUVm was significantly higher in patients than in controls in all vessels explored and correlated with acute-phase reactants and serum IL-6. Mean of the SUVm at all the vascular territories had an area under the curve (AUC) of 0.830, and a cut-off of 1.89 yielded a sensitivity of 80% and a specificity of 79% for GCA diagnosis. There were no significant differences in AUC among the vascular beds examined.
CONCLUSIONS: FDG uptake by large vessels has a substantial sensitivity and specificity for GCA diagnosis. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

Entities:  

Keywords:  acute-phase reactants; diagnosis; giant-cell arteritis; imaging; inflammation; interleukin-6; large-vessel vasculitis; positron-emission tomography

Mesh:

Substances:

Year:  2014        PMID: 24665112     DOI: 10.1136/annrheumdis-2013-204572

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  38 in total

1.  Arterial lesions in giant cell arteritis: A longitudinal study.

Authors:  Tanaz A Kermani; Sehriban Diab; Antoine G Sreih; David Cuthbertson; Renée Borchin; Simon Carette; Lindsy Forbess; Curry L Koening; Carol A McAlear; Paul A Monach; Larry Moreland; Christian Pagnoux; Philip Seo; Robert F Spiera; Kenneth J Warrington; Steven R Ytterberg; Carol A Langford; Peter A Merkel; Nader A Khalidi
Journal:  Semin Arthritis Rheum       Date:  2018-05-09       Impact factor: 5.532

2.  [Large vessel vasculitis : Giant cell arteritis and Takayasu arteritis].

Authors:  P M Villiger
Journal:  Z Rheumatol       Date:  2017-08       Impact factor: 1.372

3.  The value of ultrasound in diagnosing extracranial large-vessel vasculitis compared to FDG-PET/CT: A retrospective study.

Authors:  Christian Löffler; Johannes Hoffend; Urs Benck; Bernhard K Krämer; Raoul Bergner
Journal:  Clin Rheumatol       Date:  2017-05-15       Impact factor: 2.980

4.  Simple dichotomous assessment of cranial artery inflammation by conventional 18F-FDG PET/CT shows high accuracy for the diagnosis of giant cell arteritis: a case-control study.

Authors:  Berit Dalsgaard Nielsen; Ib Tønder Hansen; Stine Kramer; Ate Haraldsen; Karin Hjorthaug; Trond Velde Bogsrud; June Anita Ejlersen; Lars Bjørn Stolle; Kresten Krarup Keller; Philip Therkildsen; Ellen-Margrethe Hauge; Lars Christian Gormsen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-07-31       Impact factor: 9.236

5.  18 F-Fluorodeoxyglucose-Positron Emission Tomography As an Imaging Biomarker in a Prospective, Longitudinal Cohort of Patients With Large Vessel Vasculitis.

Authors:  Peter C Grayson; Sara Alehashemi; Armin A Bagheri; Ali Cahid Civelek; Thomas R Cupps; Mariana J Kaplan; Ashkan A Malayeri; Peter A Merkel; Elaine Novakovich; David A Bluemke; Mark A Ahlman
Journal:  Arthritis Rheumatol       Date:  2018-02-06       Impact factor: 10.995

6.  Three days of high-dose glucocorticoid treatment attenuates large-vessel 18F-FDG uptake in large-vessel giant cell arteritis but with a limited impact on diagnostic accuracy.

Authors:  Berit Dalsgaard Nielsen; Lars Christian Gormsen; Ib Tønder Hansen; Kresten Krarup Keller; Philip Therkildsen; Ellen-Margrethe Hauge
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-04-18       Impact factor: 9.236

7.  Comparison of magnetic resonance angiography and 18F-fluorodeoxyglucose positron emission tomography in large-vessel vasculitis.

Authors:  Kaitlin A Quinn; Mark A Ahlman; Ashkan A Malayeri; Jamie Marko; Ali Cahid Civelek; Joel S Rosenblum; Armin A Bagheri; Peter A Merkel; Elaine Novakovich; Peter C Grayson
Journal:  Ann Rheum Dis       Date:  2018-04-17       Impact factor: 19.103

8.  Risk of ischaemic events at giant cell arteritis diagnosis according to PET/CT findings.

Authors:  Jaume Mestre-Torres; Marc Simó-Perdigó; Fernando Martínez-Valle; Ignacio Navales; Jose Loureiro-Amigo; Roser Solans-Laque
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-05-12       Impact factor: 9.236

9.  Imaging acquisition technique influences interpretation of positron emission tomography vascular activity in large-vessel vasculitis.

Authors:  Kaitlin A Quinn; Joel S Rosenblum; Casey A Rimland; K Bates Gribbons; Mark A Ahlman; Peter C Grayson
Journal:  Semin Arthritis Rheum       Date:  2019-07-24       Impact factor: 5.532

10.  The prognostic value of baseline (18)F-FDG PET/CT in steroid-naïve large-vessel vasculitis: introduction of volume-based parameters.

Authors:  L Dellavedova; M Carletto; P Faggioli; A Sciascera; A Del Sole; A Mazzone; L S Maffioli
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-08-08       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.